Back to search results

PYLARIFY PET-CT for Detecting Metastasis in Pancreatic, Liver, and Breast Cancer

This study is looking at how well a special imaging scan, called PYLARIFY PET-CT, can find cancer that has spread (metastasis) in people with pancreatic cancer, hepatocellular carcinoma (a type of liver cancer), or breast cancer. You would receive Piflufolastat F18 through a vein (IV) as part of this scan. The researchers want to see if the results from the PYLARIFY PET-CT match up with other ways doctors determine if cancer has spread. They also want to understand how useful this scan is in real-world medical care. This study is currently recruiting 36 participants who are at least 18 years old and meet certain health criteria.

Study design
This is an interventional study, meaning participants will receive a specific treatment or intervention. It plans to enroll 36 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will measure accuracy through study completion, which is an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05394259

A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer

Active, Not Recruiting
PHASE1Ages 18+InterventionalDiagnostic
M.D. Anderson Cancer Center
~20 participants
Updated 2026-08-20 on ClinicalTrials.gov
What's tested:Piflufolastat F18

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Accuracy is defined as the number of concordant cases between PYLARIFY PET-CT and the gold standard truth divided by the total sample size.
Measured over through study completion, an average of 1 year

Conditions

Pancreatic Cancer
Breast Cancer
Hepatocellular Carcinoma

Explore related trials

Hepatocellular CarcinomaInvasive Breast Lobular CarcinomaPancreatic Ductal AdenocarcinomaSolid Neoplasm

NCT05394259

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • MD Anderson Cancer Center

    Houston, Texasno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Yang Lu, MD, PHD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

What this trial measures

  • Accuracy is defined as the number of concordant cases between PYLARIFY PET-CT and the gold standard truth divided by the total sample size.through study completion, an average of 1 year